A recent survey conducted by Morgan Stanley reveals that the use of GLP-1 drugs, popular for weight loss and diabetes, is affecting consumers’ spending habits, particularly in the food industry.  Novo Nordisk A/S’s (NYSE:NVO) Wegvoy (semaglutide) and Eli Lilly And Co’s (NYSE:LLY) Zepbound (tirzepatide) have amassed stupendous popularity as miracle weight loss drugs, as makers struggle to cope up with the demand.  Related: Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025. The survey, involving 300 individuals currently on GLP-1 medication, indicates a significant decrease in appetite among users, leading to reduced spending on food in restaurants and grocery stores. The survey findings suggest that ...